Thermo Fisher: ‘Biopharma’s drive for efficiency plays into our sweet spot’

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Jürgen François
Image: iStock/Jürgen François
Increased biologics both on the market and in development and demand for greater manufacturing efficiencies have led to another strong quarter for Thermo Fisher.

For the second quarter 2016, Thermo Fisher announced sales across its divisions of $4.5bn (€4.1bn), up 6% on the same period last year.

“Growth in our bioproduction business was particularly strong,”​ said CEO Marc Casper, contributing to a 14% year-on-year growth to $1.3bn within the firm’s Life Science Solutions segment.

“We’re seeing strong demand from drugs getting on market, where [we see] volume really pick up,” ​he told investors during a conference call yesterday.

But Thermo Fisher is also benefitting from the growing number of drugs currently in the process development stage, he continued, while “vaccine production and the increase in vaccines is a big driver of demand.”

He added that currently the quality of the research by biopharma is turning a greater number of entities into clinical and commercialised products, which in turn is driving demand for Thermo Fisher’s own products.

“Even in what I think is very good end-markets, there is an efficiency driver amongst that customer base - whether it’s small biotech or large pharma - and that plays to our sweet spot for sure.

“We see it in the results across quarter in and quarter out, the very strong performance in the biopharma customer set for us. So, we feel very well-positioned in a good end-market.”

The quarter also mirrored a number of Thermo Fisher’s rival vendors​ in seeing growth on the back of demand for single-use technologies, an area Casper was confident would continue to drive sales going forward.

“There has been a very large shift from stainless steel to single-use, and that also accentuates the good growth in the market,”​ he said. “That’s been an excellent growth market for a number of years for us and one with a very bright future.”

Related news

Show more

Related products

An Intense Focus on Perfusion

An Intense Focus on Perfusion

MilliporeSigma | 09-Oct-2017 | Technical / White Paper

Continuous manufacturing technologies are seeing increased industry uptake, particularly perfusion systems and, increasingly, intensified perfusion. Perfusion...

A Trusted Resin Provider For Over 35 Years

A Trusted Resin Provider For Over 35 Years

Purolite Life Sciences | 18-Sep-2017

Watch our video above to learn more about the history of Purolite Life Sciences.To discuss how we can assist your journey to process excellence, please...

The Next Stage – Eppendorfs new Mastercycler X50

The Next Stage – Eppendorfs new Mastercycler X50

Eppendorf for Bioprocess – Solutions that grow with you | 05-Sep-2017 | Application Note

The Mastercycler X50 is Eppendorf's new PCR cycler with lots of new benefits. Not only can you heat with 10°C/s, you can also optimize two different...

Survey Report: State of the Biopharmaceutical Industry 2016

Survey Report: State of the Biopharmaceutical Industry 2016

William Reed Business Media: Publish your Technical Paper on this Website | 14-Jun-2016 | Insight Guide

In May 2016, BioPharma-Reporter conducted its inaugural ‘state of the industry’ survey. The key objective of the poll was to gauge views about the current...

Related suppliers